---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-014801"
form_type: "8-K"
ticker: "ALEC"
cik: "0001653087"
company_name: "Alector, Inc."
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T04:13:19.144351+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Alector Q2 net income $9.9M, cash $808.9M; AL044 IND submitted

## Summary
- Net income $9.9M ($0.12/share) vs net loss $55.1M ($0.69) in Q2 2021; collaboration revenue rose to $79.9M from $6.6M.
- Cash, equivalents and investments $808.9M; estimated runway into second half of 2024.
- IND submitted for AL044 targeting MS4A, a genetic risk locus for Alzheimer's; first study in healthy volunteers planned.
- Expanding sites for INFRONT-3 Phase 3 of latozinemab in FTD-GRN; Phase 1 data for AL101 expected later 2022.
- Peter Heutink appointed CSO; John Maraganore as strategic advisor; AbbVie terminates CD33 collaboration (AL003).

## SEC filing metadata
- accession: 0000950170-22-014801
- form_type: 8-K
- ticker: ALEC
- cik: 0001653087
- company_name: Alector, Inc.
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1653087/000095017022014801/0000950170-22-014801-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1653087/000095017022014801/alec-20220804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-014801
- JSON: https://secwatch.observer/filing/0000950170-22-014801.json
- Plain text: https://secwatch.observer/filing/0000950170-22-014801.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.